HC Wainwright Cuts Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $11.00

Reviva Pharmaceuticals (NASDAQ:RVPH) had its price objective decreased by HC Wainwright from $14.00 to $11.00 in a research note published on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.25) EPS, FY2024 earnings at ($1.00) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.82) EPS.

RVPH has been the subject of several other reports. D. Boral Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Reviva Pharmaceuticals in a research report on Tuesday. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Maxim Group upgraded Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, January 10th. Finally, Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.40.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ RVPH opened at $1.91 on Wednesday. The stock has a market cap of $63.87 million, a P/E ratio of -1.72 and a beta of -0.12. The firm has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $1.33. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.83.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Drive Wealth Management LLC acquired a new position in shares of Reviva Pharmaceuticals during the 4th quarter valued at $36,000. EMC Capital Management grew its holdings in Reviva Pharmaceuticals by 142.0% in the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after purchasing an additional 26,134 shares during the period. Finally, Geode Capital Management LLC increased its stake in Reviva Pharmaceuticals by 17.9% in the third quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after purchasing an additional 42,376 shares in the last quarter. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.